Salmonella Research Today is a free monthly online journal that collates and summarizes the latest research about Salmonella, including details on salmonella typhimurium, food poisoning, infection, treatment.

Salmonella choleraesuis as an anticancer agent in a syngeneic model of orthotopic hepatocellular carcinoma.

Lee CH, Wu CL, Shiau AL

Department of Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan.

Some anaerobic and facultative anaerobic bacteria represent novel therapeutic agents that have been recently applied in cancer therapy. Previously, we found that Salmonella choleraesuis in combination with cisplatin could retard tumor growth in the murine subsutaneous hepatocellular carcinoma (HCC) model. In this regard, we investigated the antitumor activity of S. choleraesuis in the ML-1 orthotopic tumor model. Systemically administered S. choleraesuis accumulated within not only subcutaneous but also orthotopic tumors for at least 30 days, forming tumor-to-normal tissue ratios exceeding 1,000-10,000 to 1. The antitumor effects of S. choleraesuis were evaluated in mice bearing subcutaneous and orthotopic ML-1 tumors. Compared with the control treatment, S. choleraesuis significantly prolonged the animal survival, reduced the tumor size, as well as upregulated interferon (IFN)-gamma and induced IFN-inducible chemokines CXCL10 (IP-10) productions. Furthermore, immunohistochemical staining of the tumors revealed decreased intratumoral microvessel density, increased infiltration of neutrophils, CD4(+) and CD8(+) T cells, and induced cell death in tumor microenvironment. In conclusion, these results suggest that tumor-targeted therapy using S. choleraesuis, which exerts tumoricidal and antiangiogenic activities, represents a potential strategy for the treatment of HCC.

Published 20 December 2007 in Int J Cancer, 122(4): 930-5.
Full-text of this article is available online (may require subscription).

© 2004-2008 Salmonella Research Today. All Rights Reserved.